Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)-Reference-Cited by-同舟云学术

Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)

Published:2024-08-13 Issue:1 Volume:29 Page:
ISSN:2047-783X
Container-title:European Journal of Medical Research
language:en
Short-container-title:Eur J Med Res

Author:

Agafina Alina,Aguiar Valeria Cristina,Rossovskaya Maria,Fartoukh Muriel Sarah,Hajjar Ludhmila Abrahao,Thiéry Guillaume,Timsit Jean-François,Gordeev Ivan,Protsenko Denis,Carbone Javier,Pellegrini Rita,Stadnik Claudio Marcel Berdun,Avdeev Sergey,Ferrer Miquel,Heinz Corina C,Häder Thomas,Langohr Patrick,Bobenhausen Iris,Schüttrumpf Jörg,Staus Alexander,Ruehle Markus,Weissmüller Sabrina,Wartenburg-Demand Andrea,Torres Antoni

Funder

Biotest AG

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s40001-024-02008-x.pdf

Reference63 articles.

1. Camporota L, Cronin JN, Busana M, Gattinoni L, Formenti F. Pathophysiology of coronavirus-19 disease acute lung injury. Curr Opin Crit Care. 2022;28:9–16.

2. WHO. Report of the WHO-China joint mission on coronavirus disease. 2019. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed 29 Jan 2024.

3. National Institutes of Health (NIH). COVID-19 treatment guidelines panel. coronavirus disease 2019 (COVID-19) treatment guidelines. https://www.covid19treatmentguidelines.nih.gov/. Accessed 29 Jan 2024.

4. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensiv Care Med. 2020;46:846–8.

5. Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020;95:304–7.